LOS ANGELES, CA, NeOnc Technologies, a clinical stage medical biotechnology company, has completed a $10.0 million equity funding round.
NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has completed a $10.0 million equity funding round at a post-money valuation of $70 million.
The funding participants included Eminent II Venture Capital (the investment arm of TaiAn Venture Funds), Orion BioScience, and Lin Family Office.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
